UTAA-91

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameUTAA-91
Drug Alias NameUTAA91UTAA-91
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy > Chimeric antigen receptor γδT cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicMyositis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicMyositis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A